2021 annual financial data
Allogene Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -480.17%.
Operating income was -255,792,000 USD and net income was -244,837,000 USD.
Operating cash flow was -184,812,000 USD.
Get free Allogene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 38,489,000 USD
- Operating income
- -255,792,000 USD
- Net income
- -244,837,000 USD
- Operating cash flow
- -184,812,000 USD